Atossa Therapeutics (ATOS) Cash from Operations (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Cash from Operations of 9600000.0 for Q1 2026, down 61.1% year-over-year from 24679206.21 in Q1 2025, and up 9.43% quarter-over-quarter from 10600000.0 in Q4 2025.
Atossa Therapeutics (ATOS) Cash from Operations (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Cash from Operations for 16 consecutive years, with 9600000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 61.1% year-over-year to 9600000.0; the TTM figure through Mar 2026 stood at 33441000.0 (down 50.02% YoY), while the FY2025 annual figure was 29800000.0, down 41.7% from the prior year.
- Cash from Operations improved to 9600000.0 in Q1 2026 per ATOS's latest filing, from 10600000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 3883000.0 in Q3 2023 and bottomed at 10600000.0 in Q4 2025.
- Historically, Cash from Operations has averaged 6007705.88 across 5 years, with a median of 5571000.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 76.68% — and 2024, when it jumped 33.1%.
- Atossa Therapeutics' Cash from Operations stood at 4523000.0 in 2022, then dropped by 23.17% to 5571000.0 in 2023, then fell by 26.57% to 7051000.0 in 2024, then tumbled by 50.33% to 10600000.0 in 2025, then rose by 9.43% to 9600000.0 in 2026.
- Business Quant data shows ATOS's Cash from Operations at 9600000.0 in Q1 2026, 10600000.0 in Q4 2025, and 6000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | -9.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.63 Mn |
| Jun 30, 2026 | -9.63 Mn |
| Mar 31, 2026 | -9.60 Mn |
| Mar 31, 2026 | -9.60 Mn |
| Dec 31, 2025 | -10.60 Mn |
| Dec 31, 2025 | -10.60 Mn |
| Sep 30, 2025 | -6.00 Mn |
| Sep 30, 2025 | -6.00 Mn |
| Jun 30, 2025 | -7.24 Mn |
| Jun 30, 2025 | -7.24 Mn |
| Mar 31, 2025 | -5.96 Mn |
| Mar 31, 2025 | -5.96 Mn |
| Dec 31, 2024 | -7.05 Mn |
| Dec 31, 2024 | -7.05 Mn |
| Sep 30, 2024 | -4.75 Mn |
| Sep 30, 2024 | -4.75 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Mar 31, 2024 | -4.70 Mn |
| Mar 31, 2024 | -4.70 Mn |